PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
0.97
Current Ratio > 1.5x CRVO's 0.24. David Dodd would confirm if this surplus liquidity is put to good use.
0.97
Quick Ratio > 1.5x CRVO's 0.24. David Dodd would verify if the company can handle unexpected shortfalls much better.
0.00
Below 0.5x CRVO's 0.02. Michael Burry could foresee potential liquidity shocks if times get tough.
-2.29
Both companies show negative interest coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
No Data
No Data available this quarter, please select a different quarter.